# South Korea Diabetic Retinopathy Market > South Korea Diabetic Retinopathy Market Research Report: Size, Share, Trend Analysis By Types (Non-Proliferative Diabetic Retinopathy (NPDR), Proliferative Diabetic Retinopathy (PDR), By Treatment (Pharmacological Therapies, Laser Treatment, Surgery), and By End-user (Hospitals & Clinics, Ophthalmology Centers, Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.34% - **2024:** $ 244.2 Million - **2025:** $ 262.12 Million - **2035:** $ 532.1 Million - **Key Players:** Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Pfizer (US), Alimera Sciences (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE), Eyenovia (US) **Report ID:** MRFR/HC/48705-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-korea-diabetic-retinopathy-market-50462 --- ## Market Summary ## **South Korea Diabetic Retinopathy Market Overview** As per MRFR analysis, the South Korea Diabetic Retinopathy Market Size was estimated at 137.92 (USD Million) in 2023. The South Korea Diabetic Retinopathy Market is expected to grow from 144.8 (USD Million) in 2024 to 482 (USD Million) by 2035. The South Korea Diabetic Retinopathy Market CAGR (growth rate) is expected to be around 11.553% during the forecast period (2025 - 2035). ### **Key South Korea Diabetic Retinopathy Market Trends Highlighted** The rising prevalence of diabetes in the population, which has increased dramatically in recent years due to changes in lifestyle and an aging population, is driving notable developments in the diabetic retinopathy market in South Korea. Healthcare providers are putting more of an emphasis on creating cutting-edge diagnostic technologies like optical coherence tomography and retinal imaging as a result of the South Korean government's desire to establish early detection and treatment programs. This focus on technology is improving detection accuracy and increasing patient awareness of diabetic retinopathy, which is encouraging more people to get frequent eye exams. As telemedicine becomes increasingly ingrained in healthcare procedures, opportunities in this sector are also growing. Patients can obtain timely care thanks to the convenience of remote monitoring and consultations, particularly in areas with limited access to specialised services. Furthermore, development possibilities are further stimulated by pharmaceutical companies' active engagement in developing novel medicines, such as anti-VEGF injections. There is a lot of opportunity to investigate cutting-edge therapy approaches that can enhance patient outcomes because the government funds research projects and promotes collaborations between academic institutions and business. In South Korea, patient-centered care models are becoming more popular, according to recent trends. In order to effectively manage chronic illnesses like diabetes and its consequences, this method incorporates individualised treatment programs that take into account each patient's needs and preferences. Additionally, patient and healthcare provider education programs are becoming increasingly common, which helps lower the prevalence of diabetic retinopathy by promoting lifestyle changes and preventive measures. All things considered, the South Korean market for diabetic retinopathy is developing quickly, marked by chances for collaboration, technical breakthroughs, and a move towards patient treatment that is holistic. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **South Korea Diabetic Retinopathy Market Drivers** ### **Increasing Diabetes Prevalence** The rising prevalence of diabetes is one of the most significant drivers for the South Korea Diabetic Retinopathy Market. According to the Korea Centers for Disease Control and Prevention, the number of adults aged 30 and above diagnosed with diabetes has increased by approximately 12% in the past five years, translating to around 6 million individuals currently living with the condition. This growth in diabetes patients directly correlates with higher incidences of diabetic retinopathy, as studies indicate that about 30% of individuals with diabetes may develop this eye condition. Additionally, the South Korean government has initiated several health campaigns aimed at early detection and management of diabetes, which further boosts the demand for screening and treatment solutions in the diabetic retinopathy sector. By prioritizing preventive healthcare and meeting the growing needs of this demographic, the South Korea Diabetic Retinopathy Market is poised for substantial growth in the upcoming years. ### **Advancements in Diagnostic Technologies** Technological advancements in diagnostic methods are significantly contributing to the expansion of the South Korea Diabetic Retinopathy Market. Innovations such as Optical Coherence Tomography (OCT) and smartphone-based retinal imaging have enhanced the ability to diagnose diabetic retinopathy at earlier stages. For instance, a recent initiative in South Korea has involved the integration of Artificial Intelligence (AI) in retinal image analysis, improving accuracy rates by over 20% compared to traditional methods. Notably, the Ministry of Health and Welfare is promoting the adoption of these advanced technologies, leading to a surge in the market as more healthcare facilities invest in state-of-the-art diagnostic equipment for timely and effective screening. ### **Government Initiatives and Funding for Eye Health** The South Korean government is making significant investments in eye health and diabetic retinopathy prevention, which serves as a major driver for the market. Recent policy changes have resulted in the allocation of a multimillion-dollar budget aimed at improving eye disease management and prevention strategies. The government aims to decrease the incidence of diabetic retinopathy through extensive screening programs and public awareness campaigns focused on diabetes control. These initiatives not only support existing healthcare infrastructure but also encourage research and development within the market. Organizations such as the Korean Ophthalmological Society are actively collaborating with the government to enhance treatment accessibility, ultimately bolstering the South Korea Diabetic Retinopathy Market. ## **South Korea Diabetic Retinopathy Market Segment Insights** ### **Diabetic Retinopathy Market Type Insights** The Type segment of the South Korea Diabetic Retinopathy Market primarily encompasses Non-Proliferative Diabetic Retinopathy (NPDR) and Proliferative Diabetic Retinopathy (PDR), each displaying its own characteristics and significance within the overall landscape of diabetic eye diseases. NPDR is typically the early stage of diabetic retinopathy, characterized by microaneurysms and retinal hemorrhages. It represents a considerable portion of the diabetic retinopathy patient population in South Korea, making awareness and early diagnosis crucial in preventing progression to more severe stages. This underlines the importance of regular eye examinations, especially as the prevalence of diabetes continues to increase in the country. South Korea's growing aging population further enhances the significance of monitoring NPDR, as older adults are at a higher risk for developing diabetes and its corresponding ocular complications. On the other hand, PDR is more advanced and poses a higher risk of vision loss. In this stage, new blood vessels grow abnormally on the retina, which can lead to further complications such as vitreous hemorrhage and retinal detachment. Given that PDR can cause severe visual impairment, health authorities in South Korea are increasingly focusing on both treatment and prevention strategies tailored to manage this critical segment effectively. The rise in diabetes prevalence and advancements in screening technology are boosting efforts to diagnose both NPDR and PDR at earlier stages, leading to timely intervention. The market's growth is likely driven by innovations in therapy options and an increased emphasis on patient education regarding diabetes management and eye health. Health campaigns promoting awareness of diabetic retinopathy could lead to improved treatment outcomes, significantly benefiting individuals affected by NPDR and PDR. Moreover, the shifting dynamics of healthcare in South Korea, including the integration of telemedicine and enhanced access to ophthalmological services, position these segments for meaningful engagement and improvement in patient care and, ultimately, market growth. In summary, the Type segment's characteristics and challenges reflect the broader trends of a healthcare system increasingly concerned with outcomes related to diabetes and its complications in the context of the South Korean healthcare landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Diabetic Retinopathy Market Treatment Insights** The Treatment segment of the South Korea Diabetic Retinopathy Market plays a pivotal role in addressing the increasing prevalence of this condition among the population. Pharmacological therapies, which are designed to manage diabetic retinopathy effectively, focus on utilizing advanced medications that can slow disease progression and improve patient outcomes. Laser treatment remains a vital option due to its effectiveness in targeting specific areas of the retina, significantly reducing vision loss risks. Additionally, surgical interventions are critical as they offer solutions for advanced cases, aiming to restore vision and improve quality of life. Given the rising incidence of diabetes in South Korea, the demand for these treatments is expected to grow. The South Korean government has initiated various health programs to enhance awareness and accessibility of diabetic retinopathy treatments, thus encouraging early detection and intervention. The ongoing Research and Development efforts in the pharmaceutical and medical device sectors also present considerable opportunities for innovation in treatment methodologies, ensuring that the South Korea Diabetic Retinopathy Market remains a dynamic and essential component of the healthcare landscape. ### **Diabetic Retinopathy Market End-user Insights** The South Korea Diabetic Retinopathy Market exhibits significant growth driven by various End-users, predominantly Hospitals and Clinics, Ophthalmology Centers, and Research Institutes. Hospitals and Clinics play a crucial role in diagnosing and treating diabetic retinopathy, accounting for a substantial share of patient care owing to their comprehensive facilities and specialist services. Ophthalmology Centers are vital as they specialize in eye health, providing advanced diagnostic and treatment options tailored to diabetic retinopathy, which enhances patient outcomes and increases access to cutting-edge therapies. Research Institutes contribute significantly by driving innovation through studies focused on new treatments and technologies, augmenting the overall understanding of diabetic retinopathy. The increasing incidence of diabetes in South Korea underscores a growing necessity for effective screening and management of diabetic retinopathy, and as the population ages, demand for specialized care from these segments is anticipated to rise. Furthermore, advancements in technology and an increase in healthcare expenditure are also pivotal growth drivers within this market, facilitating better treatment modalities. The segmentation of the South Korea Diabetic Retinopathy Market reflects the dynamic approach to managing this chronic condition, thereby addressing the unique needs of patients across varying healthcare settings. Many healthcare stakeholders are collaborating to enhance patient education and streamline referral processes, ensuring comprehensive care for those affected by diabetic retinopathy. ## **South Korea Diabetic Retinopathy Market Key Players and Competitive Insights** The South Korea Diabetic Retinopathy Market is characterized by a competitive landscape that is shaped by advancements in clinical research, technology, and an increasing prevalence of diabetes within the region. As the understanding of diabetic retinopathy grows, so too does the emphasis on innovative treatments and diagnostic tools. Key players in the market are focusing on enhancing their offerings, which include a blend of pharmaceutical interventions, surgical options, and advanced imaging techniques. Competitive dynamics are influenced not only by the leading healthcare facilities and pharmaceutical companies but also by the collaborative efforts involving researchers, specialists, and technology developers. This collaborative ecosystem is vital for addressing the challenges presented by diabetic retinopathy, which requires a multifaceted approach involving early detection and effective treatment methods. Asan Medical Center is recognized as a leading institution in the South Korean healthcare landscape, especially in the context of diabetic retinopathy. The center boasts a strong reputation for its comprehensive ophthalmology services and a specialized team dedicated to the diagnosis and management of diabetic eye diseases. Its state-of-the-art facilities enable the application of advanced diagnostic tools and treatment modalities, allowing the center to provide cutting-edge care to patients suffering from diabetic retinopathy. The distinguished reputation of Asan Medical Center is enhanced by its commitment to continuous research and development in the field, positioning it as a central player in improving patient outcomes related to diabetic retinopathy across South Korea. Seoul National University Hospital plays a pivotal role in the South Korea Diabetic Retinopathy Market, characterized by its integration of research, education, and patient care. The hospital is renowned for its skilled professionals who specialize in various aspects of ophthalmology, particularly in treating diabetic retinopathy. Its extensive range of key services includes advanced imaging technologies and therapeutic options such as laser treatments and injections for managing diabetic macular edema. The market presence of Seoul National University Hospital is distinguished by its unwavering dedication to high-quality patient care and the development of innovative treatment techniques. In recent years, the hospital has engaged in strategic collaborations and partnerships to bolster its research capabilities, paving the way for advancements in clinical practice. Its focus on education and training ensures that the next generation of ophthalmologists is well-equipped to tackle the challenges of diabetic retinopathy, further solidifying its position in this critical area of healthcare within South Korea. ### **Key Companies in the South Korea Diabetic Retinopathy Market Include:** ## **South Korea Diabetic Retinopathy Market Developments** Recent developments in the South Korea Diabetic Retinopathy Market have shown significant advancements and increased attention from various healthcare institutions and organizations. Notably, Asan Medical Center and Seoul National University Hospital have been at the forefront of pioneering Research and Development initiatives aimed at improving treatment outcomes for diabetic retinopathy. Moreover, significant growth has been reported for LG Life Science as they expand their product range related to eye care, specifically targeting patients with this condition. In the sphere of mergers and acquisitions, there have been no widely reported transactions involving the primary companies in the diabetic retinopathy segment within the last few months. However, a continual emphasis on collaborative efforts between institutions like Gangnam Severance Hospital and Korea Institute of Ophthalmic Research suggests potential future alignments aimed at enhancing patient care and treatment modalities. Furthermore, market valuations for major players such as Samsung Medical Center and Pusan National University Hospital have seen upward trends, positively impacting the competitive landscape within South Korea. Over the last couple of years, hospitals have been actively integrating advanced diagnostic tools, with significant implementations noted in early 2021. This surge in innovation and institutional collaboration highlights a focused effort towards battling diabetic retinopathy effectively within South Korea. ## **South Korea Diabetic Retinopathy Market Segmentation Insights** ### **Diabetic Retinopathy Market Type Outlook** ### **Diabetic Retinopathy Market Treatment Outlook** ### **Diabetic Retinopathy Market End-user Outlook** ## Market Drivers ### Rising Healthcare Expenditure The increase in healthcare expenditure in South Korea is a significant driver for the diabetic retinopathy market. As the government and private sectors invest more in healthcare infrastructure, there is a corresponding rise in the availability of advanced diagnostic and treatment options for diabetic retinopathy. Current data suggests that healthcare spending in South Korea is projected to grow by approximately 7% annually, which is likely to enhance access to quality care for patients suffering from diabetic retinopathy. This trend indicates a favorable environment for the diabetic retinopathy market, as increased funding can lead to the development of new technologies and improved patient management strategies. ### Government Initiatives and Funding Government initiatives aimed at combating diabetes and its complications are playing a pivotal role in shaping the diabetic retinopathy market. In South Korea, the government has implemented various programs to promote diabetes management and prevention, which include funding for research and development in diabetic retinopathy treatments. These initiatives not only enhance public health awareness but also stimulate innovation within the healthcare sector. The allocation of resources towards improving screening and treatment facilities is expected to bolster the diabetic retinopathy market. As a result, healthcare providers are likely to benefit from increased funding, leading to enhanced access to care and improved patient outcomes. ### Advancements in Treatment Modalities Recent advancements in treatment modalities for diabetic retinopathy are propelling the growth of the diabetic retinopathy market. Innovative therapies, such as anti-VEGF injections and laser treatments, have shown promising results in managing the disease and preventing vision loss. The introduction of these advanced treatment options has led to improved patient outcomes, which is likely to enhance patient compliance and increase the overall market size. In South Korea, the market for diabetic retinopathy treatments is projected to reach approximately $500 million by 2027, reflecting a compound annual growth rate (CAGR) of around 10%. This growth is indicative of the increasing reliance on advanced medical technologies to address the challenges posed by diabetic retinopathy. ### Aging Population and Diabetes Prevalence The demographic shift towards an aging population in South Korea is a significant factor influencing the diabetic retinopathy market. As individuals age, the prevalence of diabetes increases, leading to a higher incidence of diabetic retinopathy. Current statistics indicate that around 30% of diabetic patients over the age of 65 develop some form of diabetic retinopathy. This trend underscores the urgent need for effective screening and treatment solutions within the diabetic retinopathy market. Furthermore, the increasing life expectancy in South Korea suggests that the number of elderly individuals at risk for diabetic retinopathy will continue to grow, thereby driving market demand for innovative therapies and management strategies. ### Increasing Awareness of Diabetic Retinopathy The growing awareness regarding diabetic retinopathy among the South Korean population is a crucial driver for the diabetic retinopathy market. Educational campaigns and initiatives by healthcare organizations have significantly improved public knowledge about the disease and its complications. As a result, more individuals are seeking regular eye examinations, leading to early detection and treatment. This trend is reflected in the increasing number of patients diagnosed with diabetic retinopathy, which has been reported to rise by approximately 15% annually. Consequently, the demand for diagnostic tools and treatment options in the diabetic retinopathy market is expected to expand, as healthcare providers strive to meet the needs of this growing patient population. ## Future Outlook The [Diabetic Retinopathy Market](https://www.marketresearchfuture.com/reports/diabetic-retinopathy-market-5792) is projected to grow at a 7.34% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment technologies. **New opportunities:** - Development of AI-driven diagnostic tools for early detection - Expansion of telemedicine services for remote patient monitoring - Investment in innovative drug delivery systems for targeted therapies By 2035, the market is expected to achieve substantial growth, reflecting enhanced treatment options and increased patient access. ## Segment Insights ### By Type: Non-Proliferative Diabetic Retinopathy (Largest) vs. Proliferative Diabetic Retinopathy (Fastest-Growing) In the South Korea diabetic retinopathy market, Non-Proliferative Diabetic Retinopathy (NPDR) holds the largest share due to its higher prevalence among diabetes patients. This form accounts for a significant portion of diagnosed cases, providing a substantial foundation for healthcare providers to focus on diagnosis and management initiatives. In contrast, Proliferative Diabetic Retinopathy (PDR) is gaining traction rapidly as awareness increases and advancements in treatment modalities become more accessible to patients. Growth trends in the segment reveal that while NPDR dominates, PDR is emerging as a focus area for new interventions and technologies. The increasing incidence of diabetes and improved screening processes are driving the PDR market. Healthcare professionals are emphasizing timely interventions, thus contributing to the momentum behind PDR. As awareness and availability of treatment options expand, PDR is expected to experience an accelerating growth trajectory. Non-Proliferative Diabetic Retinopathy (Dominant) vs. Proliferative Diabetic Retinopathy (Emerging) Non-Proliferative Diabetic Retinopathy (NPDR) is characterized by the presence of retinal findings without neovascularization, making it the more commonly diagnosed form of diabetic retinopathy. It remains dominant due to the higher patient population experiencing this condition, which leads to consistent demand for screening and management services. Conversely, Proliferative Diabetic Retinopathy (PDR), marked by the growth of abnormal blood vessels, represents an emerging segment with increasing cases, driven by factors like the aging population and rising diabetes incidences. The dynamic nature of PDR reflects healthcare advancements, creating a compelling case for innovative treatment options that cater to the unique challenges faced by this patient group. ### By Treatment: Pharmacological Therapies (Largest) vs. Laser Treatment (Fastest-Growing) In the South Korea diabetic retinopathy market, the share of various treatment modalities shows distinct distribution. Pharmacological therapies currently hold the largest share, favored for their efficacy and ease of administration. In comparison, laser treatments, while having a smaller share, are rapidly gaining traction, primarily due to their effectiveness in halting disease progression and reducing visual loss. The growth of the treatment segment is driven by increasing diabetic population rates and advancements in treatment methodologies. The expansion of healthcare infrastructure and rising awareness about effective diabetic retinopathy treatments also contribute positively. Furthermore, technological innovations in laser procedures are expected to enhance treatment adoption, making it a significantly growing segment in the near future. Pharmacological Therapies (Dominant) vs. Surgery (Emerging) Pharmacological therapies remain the dominant force in the South Korea diabetic retinopathy market, largely due to their accessibility and established efficacy in managing diabetic retinopathy symptoms. These therapies are frequently prescribed as the primary line of treatment and include a variety of medications that target the underlying pathophysiology of the condition. Conversely, surgical treatments, while emerging as a secondary option, present a valuable alternative for patients with advanced cases. Surgeries such as vitrectomy demonstrate effective long-term outcomes but are less commonly utilized due to their associated risks and requirement for specialized medical expertise. This combination highlights the current treatment landscape where pharmacological approaches prevail, yet the importance of surgical interventions is gradually acknowledging. ### By End User: Hospitals & Clinics (Largest) vs. Ophthalmology Centers (Fastest-Growing) In the South Korea diabetic retinopathy market, Hospitals & Clinics hold the largest market share among the end-user segments, driven by their robust infrastructure and advanced treatment capabilities. These facilities cater to a significant number of patients requiring management and treatment for diabetic retinopathy, making them a critical component of the healthcare landscape. Conversely, Ophthalmology Centers are emerging as the fastest-growing segment, benefiting from specialized services and a focused approach to treating eye-related conditions. Growth trends in this segment are primarily influenced by the increasing prevalence of diabetes and the consequent rise in related complications, such as diabetic retinopathy. This scenario encourages both infrastructure investment in Hospitals & Clinics and innovation in Ophthalmology Centers. The advancements in technology and treatment options, coupled with a growing awareness among patients about eye health, further propel the expansion of these segments, ensuring they play a pivotal role in addressing diabetic retinopathy in the region. Hospitals & Clinics (Dominant) vs. Ophthalmology Centers (Emerging) Hospitals & Clinics serve as the dominant force within the South Korea diabetic retinopathy market due to their comprehensive services, which encompass a range of treatment options, patient management, and advanced diagnostic technologies. These institutions are equipped to handle complex cases and often have multidisciplinary teams to address various health issues associated with diabetes. On the other hand, Ophthalmology Centers are rapidly emerging as a crucial segment by offering specialized care for patients with diabetic retinopathy. Their focused approach and expertise in eye health allow for tailored treatment regimens that enhance patient outcomes. This specialization not only attracts a growing patient base but also drives innovation in therapies and technologies, making them essential to the evolving landscape of diabetic retinopathy care. ## Competitive Benchmarking The diabetic retinopathy market in South Korea is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Novartis (CH), Regeneron Pharmaceuticals (US), and Roche (CH) are actively engaged in enhancing their product portfolios and expanding their market presence. Novartis (CH) focuses on developing advanced therapies, particularly in gene therapy, which could potentially revolutionize treatment options. Regeneron Pharmaceuticals (US) emphasizes its robust pipeline of monoclonal antibodies, while Roche (CH) is leveraging its expertise in diagnostics to create integrated solutions for diabetic retinopathy management. Collectively, these strategies indicate a trend towards comprehensive care models that integrate treatment and monitoring, thereby intensifying competition in the market. In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of major companies is significant, as they set the pace for innovation and establish benchmarks for quality and efficacy in treatment options. This competitive dynamic fosters an environment where smaller firms may struggle to keep up, yet also encourages collaboration and partnerships to leverage shared expertise. In October 2025, Bayer (DE) announced a strategic partnership with a local biotech firm to co-develop a novel drug delivery system aimed at improving the efficacy of existing therapies for diabetic retinopathy. This collaboration is likely to enhance Bayer's competitive edge by integrating cutting-edge technology into its product offerings, thereby addressing unmet needs in patient care. The partnership underscores the importance of localized innovation in a market that demands tailored solutions. In September 2025, Alimera Sciences (US) launched a new clinical trial for its sustained-release implant designed for the treatment of diabetic macular edema, a common complication of diabetic retinopathy. This initiative not only reflects Alimera's commitment to advancing treatment options but also positions the company as a key player in the evolving landscape of diabetic eye care. The trial's outcomes could significantly influence market dynamics, particularly if the implant demonstrates superior efficacy compared to existing therapies. In August 2025, Santen Pharmaceutical (JP) expanded its operations in South Korea by establishing a new research facility dedicated to ophthalmic drug development. This move is indicative of Santen's long-term strategy to enhance its R&D capabilities and foster innovation in the diabetic retinopathy space. By investing in local research, Santen aims to better understand regional patient needs and tailor its products accordingly, which may lead to a stronger market position. As of November 2025, current trends in the diabetic retinopathy market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in treatment protocols. Strategic alliances are becoming more prevalent, as companies recognize the value of collaborative innovation in addressing complex healthcare challenges. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative treatment modalities, and reliable supply chains. This shift suggests that companies that prioritize R&D and patient-centric solutions will be better positioned to thrive in the dynamic landscape of diabetic retinopathy. ## Recent News & Developments Recent developments in the South Korea Diabetic Retinopathy Market have shown significant advancements and increased attention from various healthcare institutions and organizations. Notably, Asan Medical Center and Seoul National University Hospital have been at the forefront of pioneering Research and Development initiatives aimed at improving treatment outcomes for diabetic retinopathy. Moreover, significant growth has been reported for LG Life Science as they expand their product range related to eye care, specifically targeting patients with this condition. In the sphere of mergers and acquisitions, there have been no widely reported transactions involving the primary companies in the diabetic retinopathy segment within the last few months. However, a continual emphasis on collaborative efforts between institutions like Gangnam Severance Hospital and Korea Institute of Ophthalmic Research suggests potential future alignments aimed at enhancing patient care and treatment modalities. Furthermore, market valuations for major players such as Samsung Medical Center and Pusan National University Hospital have seen upward trends, positively impacting the competitive landscape within South Korea. Over the last couple of years, hospitals have been actively integrating advanced diagnostic tools, with significant implementations noted in early 2021. This surge in innovation and institutional collaboration highlights a focused effort towards battling diabetic retinopathy effectively within South Korea. ## Report Scope | MARKET SIZE 2024 | 244.2(USD Million) | | --- | --- | | MARKET SIZE 2025 | 262.12(USD Million) | | MARKET SIZE 2035 | 532.1(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.34% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Pfizer (US), Alimera Sciences (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE), Eyenovia (US) | | Segments Covered | Type, Treatment, End User | | Key Market Opportunities | Advancements in telemedicine and AI-driven diagnostics enhance access to diabetic retinopathy care. | | Key Market Dynamics | Rising prevalence of diabetes drives demand for advanced diabetic retinopathy treatments and technologies in South Korea. | | Countries Covered | South Korea | ## Frequently Asked Questions **Q: What is the current market valuation of the diabetic retinopathy market in South Korea as of 2024?** A: The market valuation was $244.2 Million in 2024. **Q: What is the projected market size for diabetic retinopathy in South Korea by 2035?** A: The projected market size is $532.1 Million by 2035. **Q: What is the expected CAGR for the diabetic retinopathy market in South Korea during the forecast period 2025 - 2035?** A: The expected CAGR is 7.34% during the forecast period 2025 - 2035. **Q: Which companies are the key players in the South Korean diabetic retinopathy market?** A: Key players include Novartis, Regeneron Pharmaceuticals, Roche, Bayer, Pfizer, Alimera Sciences, Santen Pharmaceutical, Horizon Therapeutics, and Eyenovia. **Q: What are the main segments of the diabetic retinopathy market in South Korea?** A: The main segments include Type, Treatment, and End User. **Q: What was the market valuation for Non-Proliferative Diabetic Retinopathy (NPDR) in 2024?** A: The market valuation for NPDR was $122.1 Million in 2024. **Q: How much is the Proliferative Diabetic Retinopathy (PDR) segment expected to grow by 2035?** A: The PDR segment is projected to grow to $266.0 Million by 2035. **Q: What are the projected revenues for pharmacological therapies in the diabetic retinopathy market by 2035?** A: Projected revenues for pharmacological therapies are expected to reach $180.0 Million by 2035. **Q: What is the expected revenue for laser treatment in the diabetic retinopathy market by 2035?** A: The expected revenue for laser treatment is projected to be $200.0 Million by 2035. **Q: Which end user segment is anticipated to have the highest revenue by 2035?** A: The Hospitals & Clinics segment is anticipated to have the highest revenue, projected at $220.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-korea-diabetic-retinopathy-market-50462*